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Abstract. Background: Mechanisms regulating breast cancer lymph node metastasis are unclear. Staining of CLEVER-1 (com-
mon lymphatic endothelial and vascular endothelial receptor-1) in human breast tumors was used, along with in vitro techniques,
to assess involvement in the metastatic process.
Methods: 148 sections of primary invasive breast cancers, with 10 yr follow-up, were stained with anti-CLEVER-1. Leukocyte
infiltration was assessed, along with involvement of specific subpopulations by staining with CD83 (mature dendritic cells, mDC),
CD209 (immature DC, iDC) and CD68 (macrophage, M). In vitro expression of CLEVER-1 on lymphatic (LEC) and blood
endothelial cells (BEC) was examined by flow cytometry.
Results: In vitro results showed that although both endothelial cell types express CLEVER-1, surface expression was only
evident on LEC. In tumour sections CLEVER-1 was expressed in blood vessels (BV, 61.4% of samples), lymphatic vessels (LV,
18.2% of samples) and in M/DCs (82.4% of samples). However, only CLEVER-1 expression in LV was associated with LN
metastasis (p = 0.027) and with M indices (p = 0.021). Although LV CLEVER-1 was associated with LN positivity there was no
significant correlation with recurrence or overall survival, BV CLEVER-1 expression was, however, associated with increased
risk of recurrence (p = 0.049). The density of inflammatory infiltrate correlated with CLEVER-1 expression in BV (p < 0.001)
and LV (p = 0.004).
Conclusions: The associations between CLEVER-1 expression on endothelial vessels and macrophage/leukocyte infiltration
is suggestive of its regulation by inflammatory conditions in breast cancer, most likely by macrophage-associated cytokines. Its
upregulation on LV, related surface expression, and association with LN metastasis suggest that it may be an important mediator
of tumor cell metastasis to LN.
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List of abbreviations
BV blood vessel
CLEVER-1 common lymphatic endothelial and
vascular endothelial receptor-1
DFI disease free interval
iDC immature dendritic cells
FFPE formalin-fixed paraffin-embedded
HEV high endothelial venules
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HUVEC human umbilical vein endothelial
cells
hTERT human telomerase reverse
transcriptase
IHC immunohistochemical
LEC lymphatic endothelial cell
LN lymph node
LV lymphatic vessel
LVI lymphovascular invasion
M macrophage
mDC mature dendritic cell
OS overall survival
1. Introduction
Tumor growth and metastasis are associated with the
formation of new blood vessels (BV) (haemangiogen-
esis) and lymphatic vessels (LV) (lymphangiogenesis).
Blood vasculature provides the interface for the trans-
fer of nutrients, fluid and immune cells into tumor
tissues. LV in tumors, in comparison, function as a
‘drainage system’ to release build-up of interstitial
pressure, and play an important role in the trafficking of
antigen presenting cells and their ‘homing’ to lymph
nodes (LN). Tumor cells also disseminate to LN via
LV however the cellular and molecular mechanisms
that regulate such cellular intra- and extravasation into
and out of LV is still, in comparison to BV, largely
unknown.
With the advent of lymphatic markers such as
VEGFR-3 [17], prox-1 [43], LYVE-1 [4], and
podoplanin (also known as D2-40 [35]), it is now possi-
ble to distinguish LV from BV. Podoplanin/D2-40 has
been used as reliable lymphatic marker in immunohis-
tochemical (IHC) studies [18, 38], with results showing
a strong correlation between lymph vessel density
(LVD) and tumor metastasis to LN in melanoma and
breast cancer [7, 25, 29]. Such LN metastasis is asso-
ciated with a worse prognosis and so it is important to
understand the molecular mechanisms regulating cell
transfer across LV. Identification of molecules involved
in this regulatory process may identify patients at high
risk of developing metastases.
CLEVER-1 (common lymphatic endothelial and
vascular endothelial receptor-1, also known as
Stabilin-1, MS-1, FEEL-1) is expressed in alterna-
tively activated (type-2) macrophages and in sinusoidal
(non-continuous) endothelial cell (EC) in various tis-
sues such as liver, spleen and lymph nodes [13, 15,
24, 34]. Double immunostaining of vessels with blood
and lymphatic endothelial cell markers (PAL-E and
LYVE-1 respectively), in fresh frozen tissue material,
have suggested that CLEVER-1 is mainly expressed
in LV and is up regulated in high endothelial venules
(HEV), or HEV-like vessels in LN, in inflamed condi-
tions (skin lesions and cancerous tissues) [14, 15, 34].
CLEVER-1 has been shown to function as a scavenger
receptor for ac-LDL and its derivatives [20], play a
role in angiogenesis [1] and, most recently, has been
hypothesized to function as an adhesion molecule for
leukocyte and tumor cell trafficking in the lymphatic
system [14, 15]. All information relating to CLEVER-1
tissue distribution has thus far come from fresh frozen
material and therefore there has been little correlation
with clinicopathological information or with regards
the prognostic significance of its expression [14, 34].
The role of CLEVER-1 as an adhesion molecule for
mononuclear cell or tumor cell adhesion to vessels
has been assessed, in vitro, using human umbilical
vein endothelial cells (HUVEC, [34]) and fresh whole
lymph node sections [14], however its role in tumor
cell adhesion to lymphatic endothelial cells in vitro
is unknown. Although the regulation of CLEVER-1
expression is not fully understood inflammation, as
discussed above, has been reported as a possible stim-
ulatory signal [14].
This study presents, for the first time, a retrospective
analysis of CLEVER-1 expression in formalin-fixed
paraffin-embedded (FFPE) archival human breast can-
cer specimens with 120 months clinical follow-up.
The involvement of different leukocyte subpopula-
tions within the tumor inflammatory infiltrate was also
examined with a view to assessing their role in reg-
ulating CLEVER-1 expression. In addition, in vitro
assessment of CLEVER-1 expression in endothelial
cell models was also investigated.
2. Materials and methods
2.1. Patients and tissue samples
148 FFPE archival specimens of primary invasive
breast cancer were retrieved from the Department
of Histopathology, Nottingham City Hospital. The
median age of patients at the time of diagnosis was 57
years (range 32–70 years). Forty one patients (28%)
were younger than 50 years. 27% of tumors were
grade I (n = 40), 30% were grade II (n = 44) and 42.5%
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grade III (n = 63). Most tumors, 67%, were stage I
(n = 99), 24% were stage II (n = 36) and 8% stage
III (n = 12) disease. Fifty (34%) of the specimens
were ≤1.5 cm. Complete clinical follow-up informa-
tion was available for all patients, with ethical approval
obtained for analysis obtained from Nottingham Local
Research Ethics Committee (REC C2020313). Not-
tingham Local Research Ethics Committee waived the
need for written informed consent. Thirty four patients
(23%) developed a regional recurrence by the time of
their last follow-up. At the time of primary diagno-
sis, 45 (30%) patients had positive LN, and 49 (33%)
had lymphovascular invasion (LVI). 21 (14%) patients
were both LN and LVI positive. IHC determination
of LVI and the expression of vascular endothelial cell
growth factors VEGF-A/-C/-D have been assessed in
this cohort of patients and results described previously
[26, 27]. The median follow-up period was 96 months
(min 3, max 120 months). Tonsil, LN and nine normal
breast tissues were also included in the study. Sections
of tonsil and LN were used as positive controls for
CLEVER-1 staining [15, 24].
2.2. Immunohistochemistry
Staining with CLEVER-1 [34] (1 : 50), immature
dendritic cell (iDC) marker CD209 (R&D Systems)
(1 : 100), mature dendritic cell (mDC) marker CD83
(Serotech) (1 : 50) and macrophage (M) marker
CD68 (Abcam) (1 : 50) was carried out on sections
from FFPE blocks of tonsil and breast cancer tissues.
CLEVER-1 staining was, in addition, conducted using
LN sections.
Paraffin Sections (4-m thick) were de-waxed
in xylene and re-hydrated in a series of descend-
ing ethanol concentrations (100–30%). Endogenous
peroxidase activity was blocked with 0.3% hydro-
gen peroxide (Sigma). Slides were washed in tap
water before antigen retrieval using proteinase K
(DAKO) (15 min at room temperature). Proteinase K
was used for CLEVER-1, CD209 and CD83 stain-
ing. Antigen retrieval for CD68 staining required
boiling slides in sodium acetate buffer (pH 6) for
20 min using a 800 W microwave. Slides were then
rinsed with TBS (pH 7.6) and non-specific binding
blocked by normal swine serum (DAKO). Follow-
ing incubation for 1 hr with the primary antibodies,
slides were washed and incubated with biotinylated
secondary antibody (StreptABComplex/HRP Duet,
Mouse/Rabbit kit, DAKOCytomation) according to
the manufacturer’s instructions. After washing, avidin
coupled to biotinylated horseradish peroxidase was
added (1 h), washed and immunoreactions visualized
using diaminobenzidine (DAB, DAKO). Specimens
were counterstained using Haematoxylin (Gill’s for-
mula, Vector Laboratories Inc.), dehydrated, re-fixed
in xylene and mounted with DPX (Fluka). Negative
controls were stained using the same procedure but
excluding primary antibody.
2.3. Microscopic analysis
CLEVER-1 expression in tumor vasculature was
examined and compared with CD34, CD31 and
podoplanin staining [27, 28], in parallel sections, to
determine the nature of the vessel [26]. CLEVER-1
expression was observed in BV, LV and M/DC and
categorized into two groups according to the presence
or absence of staining. All specimens contained inflam-
matory infiltrate (assessed by the morphology of cells,
i.e. round cells in the tumor stroma and infiltrating
tumor sheets). Inflammation was semiquantitatively
graded, depending on the level of infiltrate, into mild
or dense.
The number of M and DC present was assessed
using Chalkley point methodology [9]. Briefly, three
hotspots of positively stained cells were identified and
counted using a graticule microscope eyepiece. The
mean of the three counts represented the count for each
slide (sample index) and was used in further analysis.
Once the M/DC indices were obtained, the distribu-
tions of indices were plotted and the median used as a
cut-off point for categorization: high: ≥median, low:
<median.
Samples were examined independently by two
assessors, blinded to clinicopathological data, with
reanalysis of any discrepancies.
2.4. In vitro systems
Human telomerase reverse transcriptase (hTERT)-
transfected lymphatic endothelial cells (hTERT-LEC)
[31] were used, between passages 27–34, as a
model of LEC and cultured in EGM-2MV medium
(Clonetics). HUVEC were isolated as previously
described [16], and pooled populations, from a min-
imum of three donors, used between passages 1–4.
HUVEC were cultured in MM199 media (Sigma)
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with 20% iron fortified calf serum (PAA Laborato-
ries), L-glutamine (Sigma), HEPES buffer (Sigma),
Penicillin/Streptomycin (Sigma), EGF (Sigma) and
bFGF (Peprotech). Cells were incubated in a humidi-
fied atmosphere at 37◦C and 5% CO2.
2.5. In vitro CLEVER-1 expression
For assessment of surface CLEVER-1 expression,
by FACS analysis, endothelial cells were trypsinized,
washed then fixed in 4% formaldehyde solution in
phosphate buffered saline (PBS) and aliquoted for
further staining. For intracellular (total) expression,
trypsinized cells were fixed in 4% formaldehyde
solution in phosphate buffered saline (PBS) and per-
meabilized with saponin (40 mg/100 ml) and glucose
(0.9 g/100 ml) then aliquoted for further analysis.
2 × 105 cells were either incubated with blocking
buffer (PBS+0.1% bovine serum albumin (Sigma)),
mouse IgG1 isotype control (R&D systems) or anti-
CLEVER-1 (3–372) at 20g/ml. Antibody treated
cells were further incubated with goat anti-mouse
FITC labeled antibodies (DAKOcytomation). Cells
were then analyzed using a FACSscan flow cytometer
(Becton Dickinson, Sunnyvale, CA, USA) and Win-
MDI 2.8 software.
2.6. Statistical analysis
Statistical analysis of IHC results was performed by
correlating CLEVER-1 expression (presence/absence)
with clinicopathological parameters including estro-
gen and progesterone receptor (ER and PR) status,
lymph node and distant metastasis, levels of VEGF-A,
C and D expression, LVI, as well as density of inflam-
matory infiltrate. Chi-squared tests were used to assess
the relationship between categorized data. Overall sur-
vival (OS) and disease free interval (DFI) analyses
were performed using the Kaplan-Meier method and
the statistical significance of the differences between
groups assessed by the long-rank test. DFI was defined
as the period from the end of primary treatment until
any recurrence occurred: local (defined as tumour aris-
ing in the treated breast or chest wall); regional (defined
as tumour arising in the axillary or internal mammary
LNs); or distant (any remote site other than local and
regional). Any of these recurrences was scored as an
event, with censoring of other patients at the time of last
follow-up or death. Overall survival (OS) was defined
as the period from primary surgery until the death of
the patient.
For in vitro FACS analysis the average median flu-
orescence intensities (MFI) of CLEVER-1 expression
(with the MFI of the IgG1 isotype control subtracted)
were presented ± SEM for the indicated number of
experiments. A p value of ≤0.05 defined a signifi-
cant relationship. All statistical analysis was performed
using SPSS, version 15.0.
3. Results
3.1. CLEVER-1 is preferentially expressed, in vitro,
on the surface of lymphendothelial cells
FACS intracellular staining of total CLEVER-1
expression in proliferating hTERT-LEC and HUVEC
shows that both cell types express CLEVER-1 with
higher expression present in LEC than in HUVEC
(Fig. 1). Such an effect was not due to the different
culture media as HUVEC cultured in LEC media still
showed similar expression levels (data not shown).
Interestingly, assessment of surface expression sug-
gests that CLEVER-1 levels are significantly higher
on LEC than HUVEC. MFI for intracellular and sur-
face staining were 127 ± 8.8 and 17.3 ± 1.9 (n = 11),
respectively, in hTERT-LEC and 59.5 ± 13 (n = 4) and
4.7 ± 1.8 (n = 8), respectively, in HUVEC.
3.2. CLEVER-1 is expressed in blood vessels,
lymph vessels and Mϕ/DC in tonsils, lymph
nodes, and breast cancer tissues but only
occasionally in normal breast, and then only
in Mϕ/DC
Tonsil and LN, used as positive controls for
CLEVER-1 staining [15, 24], are rich in lymphatic
and blood vessels, including HEV, and leukocytes
with different maturation or activation status. In ton-
sils (Fig. 2A), CLEVER-1-positive cells were detected
amongst epithelial cells of the mucosal layers, most
probably Langerhan’s cells, and macrophages in the
submucosa. EC of lymphatic vessels or HEV were
also CLEVER-1 positive (Fig. 2A). Similarly, in LN,
CLEVER-1 stained ECs of the subcapsular sinusoids
in lymph vessels, or HEV, and was also positive in the
macrophages lining the nodal sinusoids (Fig. 2A). Nine
normal breast tissues were also stained for CLEVER-1
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Fig. 1. Representative cytoflorograms of surface (A and C) and intracellular (B and D) staining of CLEVER-1 expression in hTERT-LEC (A
and B) and HUVEC (C and D). Both EC express CLEVER-1 however surface expression is higher on hTERT-LEC. Red (solid) areas represent
untreated cells, black line is the IgG1 isocontrol and green (grey) represents CLEVER-1 expression as detected via 3-372 antibody staining.
which was occasionally present in M/DC found in the
intra- and inter-lobular stroma, however no staining
was observed in vessels (Fig. 2A).
In breast cancer sections, staining was conducted
on 148 sections 5 of which did not contain any
tumoral lymphatics. The nature of vessels was
assessed by parallel staining with CD34, podoplanin
and CD31 (Fig. 2B). There was some variation
in CLEVER-1 expression within the same tumor
section in that not all vessels within the section
stained positively for CLEVER-1. Positive stain-
ing was more frequent and more intense on BV
(CD34+/CD31+/podoplanin−) (n = 91, 61% of sam-
ples) than LV (CD34±/CD31+/podoplanin+) (n = 27,
18% of samples), located in both peri/intratumoral
areas, and usually associated with detection of inflam-
matory infiltrate close by. Interestingly, 82% of
samples showed positive CLEVER-1 staining of M
and DC with staining being particularly strong in areas
of dense inflammation. Adipocytes in the periphery of
the tumor sections were also positive for CLEVER-1
(Fig. 2B) – such positive staining may be related to
adipocytes or to the macrophage residing in fat tissue.
3.3. Correlations between CLEVER-1 expression
in BV/LV and clinicopathological criteria
The correlation between CLEVER-1 expression in
BV or LV with different clinicopathological criteria
was analyzed and results shown in Table 1. There were
no significant relationships between BV-CLEVER-1
and patient clinicopathological criteria. However,
the presence of CLEVER-1 in LV was significantly
correlated with ER status (p = 0.005), PR status (p =
0.006) and, interestingly, LN metastasis (p = 0.027).
To examine whether lymph/angiogenic growth fac-
tors were involved in CLEVER-1 regulation in breast
cancer, expression was correlated with VEGF-A/-C
and -D expression that had previously been assessed
in parallel sections [27]. No significant correlations
were observed. The relationship between density of
inflammation and CLEVER-1 expression was also
examined (Table 1). Dense inflammatory infiltrate was
significantly associated with CLEVER-1 expression
in BV (p = 0.041) and in LV (p < 0.001). Moreover,
a strong association resulted when CLEVER-1 expres-
sion in BV was correlated with its expression in M
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Fig. 2. (A) CLEVER-1 expression in FFPE specimens of tonsil (I), LN (II), and normal breast tissue (III). Strong CLEVER-1 staining is
detected in tonsils and in LN endothelial cells of lymphatics/HEV (black arrows). Strong expression is also found in M/DC (arrow heads).
In normal breast tissues, occasional M/DC staining with CLEVER-1 is observed but no staining in vessels is found (×400). An example of
negative control staining in a tonsil section is shown in (IV) (×200). (B) CLEVER-1 expression in breast cancer. Parallel sections were stained
with CLEVER-1 (I), podoplanin (II) and CD34 (III). CLEVER-1 was detected in both blood vessels (CD34+/podoplanin−, red/grey arrows)
and lymph vessels (CD34±/podoplanin+, black arrows). CLEVER-1 expression in vessels was variable; an example is shown where positive
(red/grey arrows) and negative (arrow heads) blood vessels are present in the same section. Panel IV shows CLEVER-1 positive staining of
adipocytes in the tumor periphery (blue/white arrows) × 200. (C) Leukocyte immunohistochemistry in breast cancer. Panels I, II and III show
mDC (CD83+ve), iDC (CD209+ve) and M (CD68+ve) leukocytes, respectively. iDC and M were more frequent in the tumor periphery but
were also found infiltrating the tumor sheets, as mentioned in the narrative very few mDC were observed. Panel IV shows a representation of a
hotspot assessment, used for determination of the iDC index. I–III ×400, IV ×200.
(p < 0.001), with similar results being obtained with LV
(p = 0.004) (Table 1). Such correlations are suggestive
of a common signal(s) between M and BV/LV that
up regulates CLEVER-1 expression in the tumor envi-
ronment. It was interesting, therefore, to investigate the
role that specific leukocyte subpopulations might play
in regulating CLEVER-1 expression. 128 breast can-
cer sections (of the 148 specimens) were stained for
the presence of iDC and mDC and 79 (pair matched)
samples stained for M (Fig. 2C). Very few mDC
were observed in sections (between 0 and 5 across
in the whole section) and, when present, were mainly
located in the stroma of peritumoral areas. All sec-
tions contained significantly more iDC and M and
were more frequently observed in peritumoral than
intratumoral areas. The median number of iDC and
M, assessed per hotspot, were 3.7 and 2, respectively.
Interestingly, when iDC/M indices were correlated
with CLEVER-1 expression in vessels, only M counts
were associated with LV expression of CLEVER-1
(p = 0.02).
In terms of OS, high M indices were associated
with poor survival (p = 0.031, data not shown), which
is in agreement with previous studies in breast cancer
[23, 41]. In the case of DFI, CLEVER-1 expression
in BV was associated with a higher rate of recurrences
(p = 0.049) (Fig. 3). Although iDC indices did not influ-
ence DFI of patients over 120 months follow-up the
majority of recurrences occurred within 60 months (for
example, a total of 28 patients had recurrences over
120 months, 20 of which occurred within 60 months)
and at a 60 month cutoff high iDC indices were sig-
nificantly associated with higher rates of recurrence
(p = 0.038) (Fig. 2). Although significant for OS high
A. Ammar et al. / Lymphatic expression of CLEVER-1 in breast cancer 73
Table 1
Correlation of CLEVER-1 expression on blood and lymph vessels with clinicopathological criteria and with iDC and M indices
Clinical-pathological criteria CLEVER-1 in blood vessels CLEVER-1 in lymph vessels
Absent n (%) Present n (%) p-value Absent n (%) Present n (%) p-value
Age ≤50 14 (34.1) 27 (65.9) 0.499 31 (75.6) 10 (24.4) 0.231
>50 43 (40.2) 64 (59.8) 90 (84.1) 17 (15.9)
Size (cm) ≤1.5 24 (48) 26 (52) 0.09 43 (86) 7 (14) 0.378
>1.5 33 (33.7) 65 (66.3) 78 (79.6) 20 (20.4)
Grade I 19 (47.5) 21 (52.5) 0.355 37 (92.5) 3 (7.5) 0.13
II 15 (34.1) 29 (65.9) 35 (79.5) 9 (20.5)
III 22 (34.9) 41 (65.1) 48 (76.2) 15 (23.8)
Stage 1 40 (40.4) 59 (59.6) 0.277 85 (85.1) 14 (14.9) 0.053
2 14 (38.9) 22 (61.1) 28 (77.1) 8 (22.9)
3 2 (16.7) 10 (83.3) 7 (58.3) 5 (41.7)
NPI Good 28 (45.9) 33 (54.1) 0.255 55 (90.2) 6 (9.8) 0.082
Moderate 25 (34.7) 47 (65.3) 55 (76.4) 17 (23.6)
Poor 4 (26.7) 11 (73.3) 11 (73.3) 4 (26.7)
ER ≤20% 18 (36.7) 31 (63.3) 0.857 34 (69.4) 15 (30.6) 0.005
>20% 37 (39.4)) 57 (60.6) 83 (88.3) 11 (11.7)
PR ≤20% 21 (33.3) 42 (66.7) 0.382 45 (71.4) 18 (26.7) 0.006
>20 32 (41.6) 45 (58.4) 69 (89.6) 8 (10.4)
DM Absent 51 (39.5) 78 (60.5) 0.512 106 (82.2) 23 (17.8) 0.5
Present 5 (31.3) 11 (68.8) 12 (75) 4 (25)
LVI Absent 40 (40.8) 58 (59.2) 0.337 82 (83.7) 16 (16.3) 0.366
Present 16 (32.7) 33 (67.3) 38 (77.6) 11 (22.4)
LN status Negative 43 (41.7) 60 (58.3) 0.221 89 (86.4) 14 (13.6) 0.027
Positive 14 (31.1) 31 (68.9) 32 (71.1) 13 (28.9)
VEGF-A Low 39 (43.3) 51 (56.7) 0.133 77 (85.6) 13 (14.4) 0.136
High 18 (31) 40 (69) 44 (75.9) 14 (24.1)
VEGF-C Low 40 (43) 53 (57) 0.107 80 (86) 13 (14) 0.071
High 16 (29.6) 38 (70.4) 40 (74.1) 14 (25.9)
VEGF-D Low 32 (57.1) 46 (50.5) 0.497 63 (80.8) 15 (19.2) 0.833
High 24 (42.9) 45 (49.5) 57 (82.6) 12 (17.4)
MVD or LVD Low 32 (41) 46 (59) 0.437 86 (84.3) 16 (15.7) 0.206
High 24 (34.8) 45 (65.2) 34 (75.6) 11 (24.4)
Inflammatory density Mild 49 (43) 65 (57) 0.041 101 (88.6) 13 (11.4) <0.001
Dense 8 (23.5) 26 (76.5) 20 (58.8) 14 (41.2)
M CLEVER-1 Absent 25 (96.2) 1 (3.8) <0.001 26 (100) 0 (0) 0.004
Present 32 (26.2) 90 (73.8) 95 (77.9) 27 (22.1)
iDC index Low <3.7 25 (53.2) 40 (50.6) 0.781 53 (52.5) 12 (48) 0.689
High ≥3.7 22 (46.8) 39 (49.4) 48 (47.5) 13 (52)
M index Low <2 16 (54.7) 22 (44.9) 0.466 35 (54.7) 3 (20) 0.021
High ≥2 14 (45.3) 27 (55.1) 29 (45.3) 12 (80)
NPI (Nottingham prognostic index); DM (distant metastasis).
M indices did not correlate with DFI over 120 months,
or when using 60 months as a cut-off. This may, how-
ever, be related to sample size as only 17 cases of the
macrophage assessed population (from a total of 23
patients with recurrences) relapsed within this time
– all 17 cases were in the high M category. It is
also interesting to note that although LV CLEVER-1
expression was significantly associated with LN posi-
tivity there was no association with either DFI or OS.
4. Discussion
Previous studies have shown that CLEVER-1 is
a novel adhesion molecule potentially involved in
tumor cell dissemination via lymphatics. Although
CLEVER-1 has been studied in fresh frozen tissue
materials, no retrospective analysis has been conducted
to investigate its correlation with clinicopathologi-
cal criteria and disease outcome. The current study
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P= 0.14‡ p= 0.038 P= 0.459‡ p= 0.248
Fig. 3. Kaplan-Meier survival curves of DFI versus CLEVER-1 expression in BV and LV, and versus iDC and M indices. There was no
statistical significance of CLEVER-1 expression in LV and recurrence rates over 120 months (p = 0.14) however BV-CLEVER-1 expression
may predict regional recurrence in breast cancer patients (p = 0.049). Dashed line represents a 60 month follow-up cut-off period. iDC index is
predictive of decreased DFI at 60 months follow-up (p = 0.038) but not at later times. ‡ Represents the p value of iDC and M at 60 months.
p< 0.05 represents statistical significance.
presents, for the first time, the results of CLEVER-1
staining in archival FFPE breast cancer material, with
long follow up (120 months).
CLEVER-1, identified by Irjala and co-workers,
is present in LN on both efferent and afferent LV
(characterized by VEGF-R3 and mannose receptor
staining) and on HEV (expressing peripheral LN
addressin) [15]. Previous studies have shown that
CLEVER-1/MS-1/Stabilin-1 is upregulated in vessels
in inflamed disease conditions of skin such as wound
healing, melanoma and psoriasis [11, 34, 37]. In
cancerous human tissues, the increase in CLEVER-1
expression has been mainly associated with tumor-
associated lymphatics and not with blood vasculature
[14].
In agreement with the expression pattern of
CLEVER-1 in normal skin [34] IHC results from the
current study show that CLEVER-1 is not expressed
in vessels of normal breast. Endothelial expression
in vitromay be related to the proliferative status of cells
in culture or to the culture conditions, being exposed to
the variety of growth factors and high serum concen-
trations, required to maintain cell viability. It would be
of interest to examine whether CLEVER-1 expression
correlated with EC proliferation, either in patient sam-
ples or in vitro. Inflammation has been suggested to up
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regulate expression in blood vessels. Lymphoid organs
such as tonsils and LN are important antigen presenting
sites; as such they contain different types of leukocytes
and at varying states of inflammation. This may explain
why HEV, along with LV, in such organs express
CLEVER-1 [15]. Tonsil and LN staining also con-
firmed that some subtypes of M/DC (assessed by their
localization and morphology) express CLEVER-1
[10, 12, 13, 24].
The current study of breast cancer, and concurrent
staining of specimens with blood and lymphatic ves-
sel endothelial markers (CD34, CD31 and podoplanin,
respectively), allowed the identification of the vessel
type. Although controversy exists regarding the topog-
raphy of lymph vessels in breast cancer [16, 17] the
current study supports the existence of tumoural lym-
phatics and that cellular interaction with lymph vessels
is not a passive process [3]. It is tempting to compare
current CLEVER-1 results with previous studies using
fresh frozen material but it should be borne in mind,
when attempting such comparisons, that previous
staining of breast cancer tissues with anti-CLEVER-1,
by Irjala and co-workers, did not use a similar approach
to distinguish the two types of vessels [14]. PAL-E
(for BV) and VEGFR-3 (for LV) were used [14] rather
than CD34/CD31/Podoplanin. It has been shown that
although VEGFR-3 is a robust marker to identify lym-
phatic vessels present in normal tissues when used in
tumors it could give false positive LV results as cer-
tain BV in the tumor environment may express it [22].
Podoplanin, in comparison, is generally accepted as
a robust marker for detection of LV [30, 32, 38, 42].
With such caveats in mind Irjala and colleagues showed
that in breast cancer CLEVER-1 was mainly expressed
in LV (100% of peritumoral and 74% of intratumoral
lymphatics, respectively) [14]. In contrast, the current
report identified only weak staining in LV with the
majority of CLEVER-1 being present in BV. This dis-
crepancy may, as mentioned above, be due to the use
of different markers to identify vessels. CLEVER-1
staining in the current study was variable in inten-
sity and, interestingly, was not positive in all vessels
within the same tumor section. The heterogeneity in
the tumor environment may be responsible for such
variations.
Although CLEVER-1 staining has been reported in
head and neck and breast cancer [14] and in melanoma
[11] limited information is available with respect to
expression and correlation with clinicopathological
criteria (i.e. only with tumor grade and LN status
[14]). Retrospective analysis using archival materials,
as in the current study, allows relationships between
CLEVER-1 expression and a variety of clinicopatho-
logical information, including survival parameters, to
be analyzed. Although CLEVER-1 was more fre-
quently expressed in BV than LV, only LV CLEVER-1
showed significant correlation with LN metastasis.
Such a statistical correlation was not obtained with
the previous work of Irjala et al. [14], possibly due
to the sample size and, as discussed above, the stain-
ing methods and markers chosen. Similarly, previous
reports of CLEVER-1 staining in breast cancer [14]
did not show any expression in tumoral leukocytes.
We report here that 82% of specimens have CLEVER-
1+ macrophages/DCs infiltrating the tumor. Stabilin-1/
CLEVER-1 has been found to be inducible in
alternatively-activated macrophages/monocytes (type-
2 or M-2) in vivo (animal models of wound healing,
melanoma and in pancreatic cancer) and in vitro [37].
CLEVER-1 expression in M-2 has been associ-
ated with a scavenging function to clear out foreign,
and some self, antigens from the ECM [20]. In the
current study, analysis of CLEVER-1 expression
resulted in a significant correlation between its expres-
sion in M and BV or LV. This suggests that cyto-
kines and other inflammatory mediators available
in the tumor microenvironment may play a role in
CLEVER-1 upregulation in both vessels and M-2.
These cytokines may be secreted by tumor associated
macrophage (TAM) however it is still unclear what
key signals initiate CLEVER-1 expression. M-2 are
generated in vitro by treating macrophages/monocytes
with IL-4 with or without glucocorticoids. Inducible
M-CLEVER-1 however is inhibited by IFN- [10].
Other inflammatory cytokines such as TNF- are
unable to produce similar regulatory effects in
macrophage/monocytes [10]. Expression of CLEVER-
1 in fat cells (or possibly in macrophages infiltrating
adipose tissue) has not been previously reported and,
like BV, LV and M, its expression and role in
this cell type requires verification and further inves-
tigation. CLEVER-1 expression in adipocytes could
indicate a function as a scavenger receptor for an
acetylated LDL derivative and storage in adipose
tissue.
The reverse correlation between LV-CLEVER-1 and
ER, and PR, status may be explained by the high
cytokine content in such tumors i.e. IL-6, IL–8, IL-10,
G-CSF, IFN-, MCP-1, MIP-1 and TNF- have been
shown to be expressed at high levels in comparison
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to normal breast tissues and were inversely correlated
with ER and PR expression [6]. The cytokine profile
that correlates with CLEVER-1 expression in vessels
in different diseases is unknown and needs further
investigation particularly, for reasons given above, the
role of IL-4/glucocorticoids and IFN-. Increased IL-4
and decreased IFN- is considered as a marker of a
shift toward a Th2 CD4 and Tc2 CD8 phenotype and
an immature immune response [8]. In addition, such
an environment promotes the formation of alterna-
tively activated Mwhich are associated with inducing
endothelial cell proliferation (angiogenesis) and inhi-
bition of CD4+ T cell proliferation [19, 36]. In the
current findings, the scarcity of mDC and the presence
of CLEVER-1 in M suggests the presence of high
levels of IL-4/glucocorticoids and low levels of IFN-
in these tumors and, therefore, of a suppressed immune
response in breast cancer patients. The inhibitory effect
of IFN- on CLEVER-1 expression could be indi-
rect as IFN- did not change CLEVER-1 expression
in vitro (data not shown). Members of the VEGF family
(A/C/D) seem not to play a direct role on CLEVER-1
expression. However, they could be involved indirectly
via increasing MVD (inducing angiogenesis) [39] and
recruiting the inflammatory infiltrate, in particular M
which further interact with the tumor environment to
produce the cytokines involved in CLEVER-1 expres-
sion. Overall, the regulation of CLEVER-1 expression
by different cytokines and the molecular mechanisms
involved are still unknown and need further exam-
ination.
The current study reports the first association
between CLEVER-1 expression and patient survival.
Results indicate that CLEVER-1 may be involved in
tumor recurrence or in spread to lymph nodes. Results
are intriguing and suggest that a larger study is war-
ranted. Spread to LN via lymphatics may be a result
of the differential surface expression of CLEVER-1 on
LEC as opposed to BEC, as shown from in vitro stud-
ies. The current study also suggests, like others, that
M indices may be an important prognostic marker to
predict tumor outcome. Although iDC indices had no
prognostic significance in terms of patient overall sur-
vival they may have a prognostic significance for early
relapse (up to 5 yrs of the initial cancer). It would be
interesting, as with CLEVER-1 expression, to conduct
a larger study to confirm this.
It is interesting to speculate upon the role CLEVER-
1 may be playing in regulating metastatic spread. No
cellular ligand for CLEVER-1 has thus far been identi-
fied but the protein plays a role in scavenging, including
degradation of acLDL and the matricellular protein
SPARC (Secreted Protein Acidic and Rich in Cys-
teine) [21]. This latter function may be important as
SPARC has various, differing, effects on EC, tumor
cells and on the extracellular matrix – all may increase
tumor metastasis. Focal adhesion is dissociated upon
addition of SPARC to EC cultures (reviewed in [5]). It
may well be that this is mediated via SPARC binding
to CLEVER-1 and subsequent increase in EC per-
meability and/or tumor cell migration across EC. In
melanoma, overexpression of SPARC by tumor cells
was associated with loss of E-/P-cadherin which cor-
relates with a more invasive type of tumor [33]. More-
over, SPARC can modulate the structure of ECM by
playing a role as an alternative substrate of ECM pro-
teins (e.g. fibronectin) for crosslinking enzymes (e.g.
transglutaminase) making it “malleable and permis-
sive” of cell migration, proliferation and differentiation
[5].
The current report suggests, in agreement with pre-
vious studies in breast cancer [23, 41], that tumors
with a high M index correlate with a worse progno-
sis. In terms of DFI, iDC indices seem to significantly
distinguish patients who are more likely to have recur-
rences within 60 months but not at longer follow-up
(i.e. 10 yr). The lack of significance at 10 years follow-
up is in accordance with previous findings in breast
cancer [2]. On the other hand, iDC indices may be
a valuable predictive tool for recurrence within 60
months follow-up. A shorter follow-up time was also
used by Treilleix and co-workers (80 months), in breast
cancer, and significant results found [40].
5. Conclusions
Limited in vitro information is available comparing
tumor cell adhesion to blood and lymph endothe-
lium and the potential role that CLEVER-1 may
play in this process. IHC data show that CLEVER-
1 expression is up-regulated on endothelial vessels
by inflammatory conditions in breast cancer, most
likely by macrophage-associated cytokines. With its
up regulation on LV, and in vitro results showing that
expression on such vessels is, unlike vascular endothe-
lium, cell surface related, it is potentially playing an
important role in mediating tumor cell metastasis to
LN. In vitro and in vivo functional studies of the role
of CLEVER-1 in tumor metastasis will be important
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to verify whether it represents a therapeutic target to
inhibit tumor cell metastatic dissemination.
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